Although the results are steadily improving, the treatment of the child with lymphoblastic leukemia in relapse remains unsatisfactory. Owing to the very nature of relapse, it is highly unlikely that future chemotherapy protocols will provide curative treatment for the majority of patients with recurrent disease. Therefore, the greatest possible emphasis must be given to further improvements and refinements in front-line (initial) therapy so as to prevent relapse from ever occurring. Our goal should be to put the relapse leukemia specialist 'out of business.'
|Original language||English (US)|
|Number of pages||25|
|Journal||Hematology/Oncology Clinics of North America|
|State||Published - Jan 1 1990|
ASJC Scopus subject areas